摘要
目的观察不同剂量的辛伐他汀对急性冠状动脉综合征患者血浆组织因子和组织因子途径抑制物的影响。方法将88例急性冠状动脉综合征患者分为对照组28例、辛伐他汀20 mg组29例和辛伐他汀40 mg组31例,在入院第2天和在平均治疗8天以后清晨空腹采血,用酶联免疫吸附法测定血浆中的组织因子活性和组织因子途径抑制物的水平。结果辛伐他汀治疗的两个组组织因子活性较治疗前明显降低,分别从0.47±0.58 IU/L下降到0.20±0.30 IU/L和从0.59±0.77 IU/L下降到0.36±0.55 IU/L(P<0.05),对照组组织因子活性无变化;辛伐他汀40 mg组组织因子途径抑制物的水平增高,从263±203μg/L增加到369±279μg/L(P<0.05),但其他两组组织因子途径抑制物水平在治疗前后无差异。结论20 mg和40 mg辛伐他汀短期治疗急性冠状动脉综合征患者均能使组织因子活性降低,40 mg辛伐他汀治疗时使组织因子途径抑制物水平增高,提示他汀对组织因子和组织因子途径抑制物的作用可能是其抗栓机理之一。
Aim To investigate the effects of different doses of simvastatin on plasma activity of tissue factor(TF) and level of tissue factor pathway inhibitor(TFPI) in patients with acute coronary syndromes(ACS). Methods A total of 88 patients with acute coronary syndromes were randomized in to three groups: control group without use of statin, group with 20 mg and group with 40 mg simvastafin therapy. The plasma activity of TF and level of TFPI were measured using IMUBIND^R enzymelinked immunosorbent assay ( ELISA ) kit. Results Both doses of simvastatin therapy can significantly decrease the activity of TF ( from 0.47 ± 0.58 IU/L to 0.20 ± 0.30 IU/L and from 0.59 ± 0.77 IU/L to 0.36 ± 0.55 IU/L, respectively) ( P 〈 0.05 ), only large dose of simvastatin (40 mg group) can increase TFPI level (from 263 ± 203 μg/L to 369 ± 279 μg/L) ( P 〈 0.05). Conclusions Simvastatin can change plasma activity of TF and level of TFPI and may have antithrombotie effect.
出处
《中国动脉硬化杂志》
CAS
CSCD
2005年第5期633-635,共3页
Chinese Journal of Arteriosclerosis
关键词
内科学
酶联免疫吸附法
急性冠状动脉综合征
组织因子
组织因子途径抑制物
他汀类
辛伐他汀
Enzyme-Linked Immunosorbent Assay
Acute Coronary Syndromes
Tissue Factor
Tissue Factor Pathway Inhibitor
HMG-COA Reduetase Inhibltors
Statins
Simvastatin